Skip to main content
. 2010 Jan 4;107(4):1547–1552. doi: 10.1073/pnas.0908801107

Fig. 2.

Fig. 2.

Anti-CD73 mAb therapy requires adaptive immunity. (A) 4T1.2 (Upper) or E0771 (Lower) tumor cells were plated in complete media with increasing doses of APCP or anti-CD73 mAb (clone TY/23) for 4 days. Tritiated thymidine was added for the last 16 h, and cells were harvested and radioactivity measured with a β-counter (P > 0.05 by Mann–Whitney test; n = 5–6 per condition; means ± SEs of one representative of three experiments are shown). (B and C) Female SCID mice were injected s.c. in the mammary fat pad with 105 4T1.2 cells (B) or 5 × 105 E0771 cells (C) and treated with 100 μg anti-CD73 mAb (TY/23) or control Ig (Mac4) two times weekly from day 3 (P > 0.05 by Mann–Whitney test; n = 5 per group; means ± SEs of one representative of two experiments are shown). (D) After treatment, spontaneous 4T1.2 lung metastases were counted at day 20 after s.c. tumor injection (*, P < 0.05 by Mann–Whitney test; n = 9 per group; symbols represent individual mice; means ± SEs of two experiments are shown).